HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Pre-IPO WuXi XDC - The Beautiful Story and the Truth Behind

Pre-IPO WuXi XDC (PHIP Updates) - Some Points Worth the Attention

Remegen (9995.HK/688331.CH) - The Survival Problem Is Becoming Imminent

Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?

Equity Capital Markets

Pu'er Lancang Ancient Tea / Equity Capital Markets

<ul>
<li>Traditional tea companies are rarely seen in China's secondary market. The most significant issue in the domestic tea industry is product standardization, leading to obvious bottlenecks in future revenue/profit scale. </li>
<li>Despite increasing investment in sales/marketing, financial results of Lancang haven’t shown much improvement. Sales of 1966 products would continue to be under pressure due to weak demand during economic downturn.</li>
<li>Lancang’s financial performance is unsatisfactory, with declining revenue growth and profit margin. We are not optimistic about the Company's prospects. Valuation should be lower than <a href="https://www.smartkarma.com/entities/nayuki-holdings" target="_blank" data-smartkarma-citation="entities:32149:1" rel="noopener">Nayuki Holdings (2150 HK).</a>
</li>
</ul>


Traditional tea companies are rarely seen in China's secondary market. The most significant issue in the domestic tea industry is product standardization, leading to obvious bottlenecks in future revenue/profit scale. 
Despite increasing investment in sales/marketing, financial results of Lancang haven’t shown much improvement. Sales of 1966 products would continue to be under pressure due to weak demand during economic downturn.
Lancang’s financial performance is unsatisfactory, with declining revenue growth and profit margin. We are not optimistic about the Company's prospects. Valuation should be lower than Nayuki Holdings (2150 HK).



Pre-IPO Pu'er Lancang Ancient Tea (PHIP Updates) - Lack of Product Standardization Is the Pain Point